Literature DB >> 34687915

Prolactinomas.

Luiz Eduardo Wildemberg1, Christhiane Fialho2, Monica R Gadelha3.   

Abstract

Hyperprolactinemia, defined by a level of serum prolactin above the standard upper limit of normal range, is a common finding in clinical practice and prolactinomas are the main pathological cause. Prolactinomas lead to signs and symptoms of hormone oversecretion, such as galactorrhea and hypogonadism, as well as symptoms of mass effect, including visual impairment, headaches and intracranial hypertension. Diagnosis involves prolactin measurement and sellar imaging, but several pitfalls are involved in this evaluation, which may difficult the proper management. Treatment is medical in the majority of cases, consisting of dopamine agonists, which present high response rates, with a very favorable safety profile. Major adverse effects that should be monitored consist of cardiac valvulopathy and impulse control disorders. Other treatment options include surgery and radiotherapy. Temozolomide may be used for aggressive or malignant carcinomas. Finally, pregnancy outcomes are similar to general population even when dopamine agonist treatment is maintained.
Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Cabergoline; Dopaminergic agonists; Hyperprolactinemia; Impulse control disorder; Prolactinomas

Mesh:

Substances:

Year:  2021        PMID: 34687915     DOI: 10.1016/j.lpm.2021.104080

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  2 in total

1.  Resolution of Visual Field Defect in Macroprolactinoma After Treatment With Cabergoline.

Authors:  Kimitaka Shibue; Momoko Yamakawa; Namiko Nishida; Akihiro Hamasaki
Journal:  Cureus       Date:  2022-05-31

Review 2.  Altered Food Behavior and Cancer: A Systematic Review of the Literature.

Authors:  Daniele Nucci; Omar Enzo Santangelo; Sandro Provenzano; Mariateresa Nardi; Alberto Firenze; Vincenza Gianfredi
Journal:  Int J Environ Res Public Health       Date:  2022-08-18       Impact factor: 4.614

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.